Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05594563 · ClinicalTrials.gov registry record · Phase 2

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

A Phase 2 study of Type 1 Diabetes, sponsored by Emily K. Sims.

Recruiting
Registry status
Phase 2
Development phase
70
Enrollment target
7
Study locations

NCT05594563 is a Phase 2 study of Type 1 Diabetes that is actively recruiting participants, run by Emily K. Sims. The registered enrollment target is 70 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05594563, a Phase 2 study of Type 1 Diabetes, is actively recruiting participants, sponsored by Emily K. Sims.

RECRUITING
Registry status
Phase 2
Development phase
70 participants
Enrollment target
7
Study locations

Study Summary

The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answer are: * Does it reduce stress on the cells that make insulin? * Does it preserve what is left of the body's insulin production? Participants will take either DFMO or a placebo (looks like DFMO but has no active ingredients) two times a day for about 6 months. Participants will have 6 in person visits and 1 phone visit over a period of 12 months. Visits will include blood draws urine collection and other tests.

Conditions Studied

Type 1 Diabetes

Interventions

  • DRUG Placebo
  • DRUG DFMO

Study Locations (7)

Colorado

  • Barbara Davis Center - Aurora

Illinois

  • University of Chicago - Chicago

Indiana

  • IU Health Riley Hospital for Children - Indianapolis

Kansas

  • Children's Mercy Hospital - Kansas City

Michigan

  • University of Michigan - Ann Arbor

Minnesota

  • MHealth Fairview Masonic Children's Hospital and Specialty Clinics - Minneapolis

Wisconsin

  • Medical College of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-03-14
Est. Completion 2028-05
Phase Phase 2

Sponsor

Emily K. Sims

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05594563

The ClinicalTrials.gov registry entry for NCT05594563 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The listed sponsor is Emily K. Sims, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05594563 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Colorado, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT05594563 about?

NCT05594563 is a clinical study titled "TArgeting Type 1 Diabetes Using POLyamines (TADPOL)". The goal of this clinical trial is to test a drug known as DFMO in people with Type 1 Diabetes (T1D). The main question\[s\] it aims to answer are: * Does it reduce stress on the cells that make insulin? * Does it preserve what is left of the body's insulin production? Participants will take either...

What is the current status of trial NCT05594563?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2023-03-14. Estimated completion is 2028-05.

What conditions does trial NCT05594563 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT05594563?

The interventions under investigation include: Placebo (DRUG), DFMO (DRUG).

Who is sponsoring clinical trial NCT05594563?

This trial is sponsored by Emily K. Sims, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05594563 being conducted?

This trial has 7 study locations across Colorado, Illinois, Indiana, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.